<?xml version="1.0" encoding="UTF-8"?>
<results title="drugs">
 <result pre="influenza viruses A (H3N2) that exhibited reduced sensitivity to both" exact="zanamivir" post="and amantadine. These rare and naturally occurring viruses harbored"/>
 <result pre="S31N mutation in M2. Keywords: Influenza A virus H3N2 subtype" exact="zanamivir" post="amantadine antiviral drug resistance viruses Myanmar expedited dispatch Adamantanes"/>
 <result pre="mutation in M2. Keywords: Influenza A virus H3N2 subtype zanamivir" exact="amantadine" post="antiviral drug resistance viruses Myanmar expedited dispatch Adamantanes and"/>
 <result pre="(H3N2) with S31N mutation in M2 limited the effectiveness of" exact="amantadine" post="(1,2). In 2008, the emergence of subtype H1N1 with"/>
 <result pre="mutation in neuraminidase (NA) raised concerns about the use of" exact="oseltamivir" post="(3,4). On the other hand, the incidence of zanamivir-resistant"/>
 <result pre="which was isolated from an immunocompromised child who underwent prolonged" exact="zanamivir" post="treatment, was reported (6). In 2008, subtype H3N2 with"/>
 <result pre="2008, subtype H3N2 with D151A/V mutations in NA demonstrated reduced" exact="zanamivir" post="sensitivity by chemiluminescent NAI assay (5). Recently, zanamivir-resistant subtype"/>
 <result pre="an S31N mutation in M2, which respectively confer reductions in" exact="zanamivir" post="and amantadine susceptibility. In 2007 and 2008, we performed"/>
 <result pre="mutation in M2, which respectively confer reductions in zanamivir and" exact="amantadine" post="susceptibility. In 2007 and 2008, we performed phenotypic and"/>
 <result pre="assay that measures the 50% inhibitory concentration (IC50) by using" exact="zanamivir" post="and oseltamivir carboxylate (9). All samples were assayed in"/>
 <result pre="measures the 50% inhibitory concentration (IC50) by using zanamivir and" exact="oseltamivir" post="carboxylate (9). All samples were assayed in duplicates in"/>
 <result pre="NAI susceptibility assay showed 1 (1.5%) isolate (A/Myanmar/M187/2007) with a" exact="zanamivir" post="IC50 value of 59.72 nM, which was collected in"/>
 <result pre="in August 2007, and 1 (0.5%) isolate (A/Myanmar/M114/2008) with a" exact="zanamivir" post="IC50 of 33.37 nM, which was collected in July"/>
 <result pre="These isolates respectively demonstrated a 53× and 30× reduction in" exact="zanamivir" post="susceptibility (Table) and were extreme outliers (data not shown)."/>
 <result pre="subtype H3N2 viruses analyzed in this study remain sensitive to" exact="oseltamivir" post="carboxylate (Table). Table Characteristics of subtype H3N2 influenza viruses"/>
 <result pre="NA genes showed that the isolates with reduced sensitivity to" exact="zanamivir" post="belonged to 2 distinct clusters (Figure 1). These viruses"/>
 <result pre="NA gene showed that the isolates with reduced sensitivity to" exact="zanamivir" post="had a glutamine (Q) to lysine (K) substitution at"/>
 <result pre="are marked with asterisks, and isolates with reduced sensitivity to" exact="zanamivir" post="with Q136K mutation in NA are marked with squares."/>
 <result pre="S31N mutation in M2, which demonstrated reduced susceptibility to both" exact="zanamivir" post="and amantadine but remained susceptible to oseltamivir. These Q136K"/>
 <result pre="in M2, which demonstrated reduced susceptibility to both zanamivir and" exact="amantadine" post="but remained susceptible to oseltamivir. These Q136K viruses were"/>
 <result pre="the isolates in the database were obtained before introduction of" exact="zanamivir" post="into clinical practice in 1999 in Australia, New Zealand,"/>
 <result pre="unknown. Further study is needed to evaluate the effectiveness of" exact="zanamivir" post="in patients infected with Q136K mutants. Continued monitoring of"/>
 <result pre="Agents Chemother. 2008;52:3284–9210.1128/AAC.00555-0818625765 6. GubarevaLV, MatrosovichM, BrennerM, BethellR, WebsterREvidence for" exact="zanamivir" post="resistance in an immunocompromised child infected with influenza B"/>
 <result pre="from Australasia and South East Asia to the neuraminidase inhibitors" exact="zanamivir" post="and oseltamivir.Antiviral Res. 2004;62:37–4510.1016/j.antiviral.2003.11.00815026200 10. TashiroM, McKimm-BreschkinJ, SaitoT, KlimovA,"/>
 <result pre="sequence analysis and susceptibilities of influenza virus clinical isolates to" exact="zanamivir" post="and oseltamivir.Antimicrob Agents Chemother. 2003;47:2264–7210.1128/AAC.47.7.2264-2272.200312821478"/>
</results>
